| Autor: |
Middaugh, C. Russell, Borchardt, Ronald T., Kerns, Edward H., Hageman, Michael J., Thakker, Dhiren R., Stevens, James L., Raub, Thomas J., Lutzke, Barry S., Andrus, Paula K., Sawada, Geri A., Staton, Brian A. |
| Zdroj: |
Optimizing the 'Drug-Like' Properties of Leads in Drug Discovery; 2006, p355-410, 56p |
| Abstrakt: |
Assessing brain exposure continues to be a central theme for multiple therapeutic areas within the pharmaceutical industry. In addition to optimizing delivery to CNS targets, brain exposure is considered for unwanted CNS access for either on-target activity or for off-target CNS toxicity or adverse events. The biopharmaceutical scientist is challenged to arrive at a rational strategy that is functional within the constraints of limited resources. Common strategies are integrated combinations of in silico, in vitro, and in vivo methods (Caldwell et al., 2001). The appropriate strategy used depends upon the need, i.e., to drive chemistry or to establish a pharmacokinetic-pharmacodynamic relationship. We believe that a rigorous strategy is best so that the best lead series are selected. The intent is to anticipate liabilities of a lead series such that subsequent lead optimization cycle time and clinical attrition rates are ultimately reduced. The rigorous methods should deliver value by aiding synthetic chemistry direction while filtering out difficult templates. We also advocate the use of animal models as early as possible to establish a realistic perspective around the plethora of higher-throughput screening assay data. This application obviously challenges one to increase the capacity of these in vivo assays without compromising data quality or wasting vital and limited people resources. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
